Loading...
XNAS
ICUI
Market cap3.22bUSD
Jul 15, Last price  
126.49USD
1D
-0.99%
1Q
-6.29%
Jan 2017
-11.20%
Name

ICU Medical Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
1.31
EPS
Div Yield, %
Shrs. gr., 5y
2.51%
Rev. gr., 5y
13.47%
Revenues
2.38b
+5.44%
157,532,000201,613,000188,138,000204,726,000231,513,000284,582,000302,195,000316,869,000313,716,000309,260,000341,668,000379,372,0001,292,613,0001,400,040,0001,266,208,0001,271,004,0001,316,308,0002,279,997,0002,259,126,0002,382,046,000
Net income
-118m
L+296.86%
20,274,00025,660,00023,079,00024,300,00026,557,00030,929,00044,669,00041,281,00040,418,00026,335,00044,985,00063,084,00068,644,00028,793,000101,035,00086,870,000103,135,000-74,286,000-29,655,000-117,688,000
CFO
204m
+22.76%
27,372,00031,608,00041,512,00030,227,00048,609,00033,095,00064,487,00066,271,00064,020,00060,640,00054,865,00089,941,000154,423,000160,215,000101,918,000222,752,000267,538,000-62,129,000166,201,000204,033,000
Earnings
Aug 05, 2025

Profile

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
IPO date
Mar 31, 1992
Employees
14,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,382,046
5.44%
2,259,126
-0.92%
2,279,997
73.21%
Cost of revenue
1,645,879
1,604,597
1,675,220
Unusual Expense (Income)
NOPBT
736,167
654,529
604,777
NOPBT Margin
30.90%
28.97%
26.53%
Operating Taxes
51,676
(48,644)
(40,123)
Tax Rate
7.02%
NOPAT
684,491
703,173
644,900
Net income
(117,688)
296.86%
(29,655)
-60.08%
(74,286)
-172.03%
Dividends
Dividend yield
Proceeds from repurchase of equity
(9,350)
(2,098)
BB yield
0.39%
0.06%
Debt
Debt current
51,000
71,161
29,688
Long-term debt
1,590,662
1,707,783
1,704,615
Deferred revenue
10,585
16,239
Other long-term liabilities
101,842
74,037
165,233
Net debt
1,333,096
1,521,101
1,520,779
Cash flow
Cash from operating activities
204,033
166,201
(62,129)
CAPEX
(79,373)
(83,893)
(99,329)
Cash from investing activities
(88,960)
(87,947)
(1,909,468)
Cash from financing activities
(55,800)
(35,979)
1,637,032
FCF
804,830
700,080
106,934
Balance
Cash
308,566
254,723
213,008
Long term investments
3,120
516
Excess cash
189,464
144,887
99,524
Stockholders' equity
553,209
757,179
758,922
Invested Capital
3,460,471
3,767,002
3,819,039
ROIC
18.94%
18.54%
25.80%
ROCE
19.90%
16.50%
14.95%
EV
Common stock shares outstanding
24,388
24,091
23,868
Price
155.17
55.57%
99.74
-36.66%
157.48
-33.65%
Market cap
3,784,286
57.49%
2,402,836
-36.07%
3,758,733
-27.29%
EV
5,117,382
3,923,937
5,279,512
EBITDA
955,679
883,320
839,928
EV/EBITDA
5.35
4.44
6.29
Interest
106,541
102,727
66,375
Interest/NOPBT
14.47%
15.69%
10.98%